CTBO (Cantabio Pharmaceuticals) Shares Buyback Ratio %: -216.67 (As of Aug. 18, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Cantabio Pharmaceuticals Shares Buyback Ratio %?

Cantabio Pharmaceuticals CTBO Shares Buyback Ratio % is -216.67 as of Aug. 18, 2026.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

GuruFocus calculates shares buyback ratio using previous shares outstanding minus the current shares outstanding, and then divides by previous shares outstanding. Cantabio Pharmaceuticals's current shares buyback ratio was -216.67%.

Cantabio Pharmaceuticals Shares Buyback Ratio % Related Terms

Cantabio Pharmaceuticals Shares Buyback Ratio % Historical Data

* Premium members only.

The historical data trend for Cantabio Pharmaceuticals's Shares Buyback Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cantabio Pharmaceuticals Shares Buyback Ratio % Chart

Cantabio Pharmaceuticals Annual Data
Trend Mar12 Mar13 Mar14 Mar15 Mar16 Mar17 Mar18
Shares Buyback Ratio %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 -100.00

Cantabio Pharmaceuticals Quarterly Data
Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18
Shares Buyback Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -20.00 -66.67 -10.00 -45.45 -18.75

Cantabio Pharmaceuticals Shares Buyback Ratio % Calculation

Cantabio Pharmaceuticals's Shares Buyback Ratio for the fiscal year that ended in Mar. 2018 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Mar. 2017 ) - Shares Outstanding (EOP) (A: Mar. 2018 )) / Shares Outstanding (EOP) (A: Mar. 2017 )
=(0.005 - 0.010) / 0.005
=-100.00%

Cantabio Pharmaceuticals's Shares Buyback Ratio for the quarter that ended in Dec. 2018 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Sep. 2018 ) - Shares Outstanding (EOP) (A: Dec. 2018 )) / Shares Outstanding (EOP) (A: Sep. 2018 )
=(0.016 - 0.019) / 0.016
=-18.75%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Shares Buyback Ratio % →
What does a Shares Buyback Ratio % of -216.67 mean?
Cantabio Pharmaceuticals (CTBO) has a Shares Buyback Ratio % of -216.67 as of Aug. 18, 2026. Share buyback ratio is the percent change of a company's shares outstanding from two periods. View historical data on Cantabio Pharmaceuticals and its competitors.
Is Cantabio Pharmaceuticals' Shares Buyback Ratio % too high?
Cantabio Pharmaceuticals' current Shares Buyback Ratio % is -216.67.
How does Cantabio Pharmaceuticals' Shares Buyback Ratio % compare to TNTY and ETNI?
Cantabio Pharmaceuticals' Shares Buyback Ratio % of -216.67 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Buyback Ratio % for a Biotechnology company?
A good Shares Buyback Ratio % depends on the Biotechnology industry context. However, Shares Buyback Ratio % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Buyback Ratio % mean?
A high Shares Buyback Ratio % can signal that a stock is expensive relative to its fundamentals. Share buyback ratio is the percent change of a company's shares outstanding from two periods. View historical data on Cantabio Pharmaceuticals and its competitors. Cantabio Pharmaceuticals's current Shares Buyback Ratio % is -216.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cantabio Pharmaceuticals stock overvalued right now?
Cantabio Pharmaceuticals (CTBO) has a current Shares Buyback Ratio % of -216.67. The current Shares Buyback Ratio % is -216.67. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Buyback Ratio % calculated?
Shares Buyback Ratio % is calculated from a company's financial statements. For Cantabio Pharmaceuticals (CTBO), the current Shares Buyback Ratio % is -216.67 as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cantabio Pharmaceuticals Business Description

Address 1250 Oakmead Parkway, Sunnyvale, CA, USA, 94085
Cantabio Pharmaceuticals Inc is the United States based preclinical stage biotechnology company. It is focused on commercializing novel therapies and the intellectual property generated from its research and development activities for Parkinson's disease and Alzheimer's disease and other related diseases. In addition, In addition, it is also engaged in the development of therapeutic proteins that can pass through the blood-brain barrier and supplement in vivo levels of proteins which display loss of function during disease conditions.